Researchers stumbled onto a surprising weakness in influenza while mapping how the virus moves inside cells, and that accident points to a new way to stop certain strains from spreading. The lab work shows different flu variants use distinct entry tactics, and a particular human protein appears essential for one major type but irrelevant for another. The finding opens a practical path toward targeted preventive drugs while also flagging the need for careful testing beyond isolated cells.
The team set out to trace viral RNA and build a clearer picture of how influenza particles assemble and exit infected cells. Instead, they found strain-level differences at the very first step: how viruses get inside lung cells. That distinction matters because blocking entry would prevent replication before it ever starts, cutting infections off at the source rather than trying to fight them after they spread.
Scientists focused on H1N1 and H3N2, two familiar influenza A types that cause most seasonal flu. Current diagnostics and frontline clinical decisions treat them the same, but these viruses are not identical in how they hijack cellular machinery. Recognizing those differences is the key to smarter, more precise antiviral strategies that hit only what the virus actually needs.
“The hope is that fundamental, curiosity-based research like this helps to pave the way for novel strategies to treat and prevent influenza infections,” principal investigator Dr. Emily Bruce, from the University of Vermont’s Larner College of Medicine, said in the SWNS report. This is the kind of basic science that builds the map before you design the road, and it shifts the focus from one-size-fits-all fixes to mechanism-specific interventions. If you can identify a human factor a virus depends on, you can consider drugs that temporarily block that factor during an outbreak.
Testing used viruses isolated from patient nasal swabs collected in 2022, and the experiments were performed in cultured human cells. The original aim was straightforward: track viral RNA segments and watch how they assemble into new virions. Along the way, the lab noticed that something in the cell was preventing entry for one strain but not the other, which pulled the team down a fresh line of inquiry.
They traced the effect to a host protein called Rab11B, depletion of which stopped H3N2 from entering lung cells while leaving H1N1 untouched. Reverse genetics helped the researchers map which viral components interacted with that pathway, revealing a role for Rab11B specific to H3N2 during the entry phase. That kind of specificity challenges long-held assumptions that all influenza A strains use the same cellular doorway.
“Viruses are like pirates from different countries hijacking someone’s ship,” Bruce said. “We had previously thought that all flu viruses used the same way to get into a cell, but we discovered that this is not true,” she went on. “H1N1 and H3N2 need different proteins to get in, and if you get rid of the right protein, a specific virus can’t get in.” Those exact observations change the way researchers should think about designing prophylactics that block entry rather than broadly targeting replication steps shared by every strain.
“You don’t get sick when a virus is in one cell,” he noted. “You get sick because a virus replicates itself and goes into many more cells.” Stopping a virus at that very first hurdle could dramatically reduce who becomes ill and how fast an outbreak grows, and it could reduce reliance on vaccines tuned to predicted strains or on antivirals that must be given after infection begins.
The researchers are careful to say the results come from isolated cell experiments, so the safety and effectiveness of blocking Rab11B in a living respiratory system remain unknown. Further work will test whether targeting that pathway causes unacceptable side effects and whether the dependency is consistent across H3N2 variants or unique to the samples tested. The next steps aim to move from petri dish proof to animal models and, eventually, to studies that reveal whether this route could support safe, targeted preventive medicines for people.
